AZN AstraZeneca
- 79.295
- -0.915-1.14%
AstraZeneca News
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
AstraZeneca's (AZN) Tagrisso SNDA Gets FDA's Priority Tag
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Centessa Pharma Hires CFO From Fusion After AstraZeneca Takeover
By Dean Seal Centessa Pharmaceuticals has hired the former chief financial officer of Fusion Pharmaceuticals after the latter company was acquired by AstraZeneca. The clinical-stage pharmaceutical c
Berenberg Raises Price Target on AstraZeneca to GBP150 From GBP130, Cites More Confidence in Longer-Term Outlook, Keeps Buy Rating
Berenberg Raises Price Target on AstraZeneca to GBP150 From GBP130, Cites More Confidence in Longer-Term Outlook, Keeps Buy Rating.
AstrraZeneca Announced Earlier Tagrisso Granted Priority Review In The US For Patients With Unresectable, Stage III EGFR-mutated Lung Cancer
AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage I
AstraZeneca Wins US FDA's Priority Review Tag for Expanded Use of Lung Cancer Drug
AstraZeneca (AZN.L, AZN.ST) said Monday the US Food and Drug Administration granted priority review for its supplemental new drug application involving its lung cancer drug Tagrisso. The biopharmaceut
Express News | AstraZeneca's Tagrisso drug for treating lung cancer has received priority review in the USA.
AstraZeneca Looks Well on Track to Reach 2030 Revenue Target -- Market Talk
0614 GMT - AstraZeneca's oncology and biopharma upgrades move the Anglo-Swedish pharma giant closer to reaching its 2030 revenue goal, Berenberg analysts say in a note. Berenberg raised its 2030 reven
Express News | On Friday, ASML Holding's Amsterdam stock price closed up 0.15% at EUR 958.90, barely reaching a new closing high for the second trading day. The stock rose 10.12% this week. As of 01:48 Beijing time on June 8th, Nvidia's stock price in the US rose by abo
FDA Advised Manufacturers Of Authorized Covid Vaccines That Covid-19 Vaccines For Use Beginning In Fall 2024 Should Be Monovalent JN.1 Vaccines
FDA Advised Manufacturers Of Authorized Covid Vaccines That Covid-19 Vaccines For Use Beginning In Fall 2024 Should Be Monovalent JN.1 Vaccines
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Germany's Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions - Interview
By Helena Smolak and Stefanie Haxel Germany's Merck KGaA is betting on artificial-intelligence partnerships to develop new drugs, but refraining from bringing in external expertise through acquisitio
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
TD Cowen analyst Steve Scala maintains $AstraZeneca(AZN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 67.1% and a total average return of 9.6% over the past year
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
Novavax Says FDA Panel Backs Update For Monovalent JN.1-Lineage; Novavax To Deliver Protein-Based JN.1 COVID Vaccine; Expects To Be Ready For Delivery In September
Novavax Says FDA Panel Backs Update For Monovalent JN.1-Lineage; Novavax To Deliver Protein-Based JN.1 COVID Vaccine; Expects To Be Ready For Delivery In September
Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During BIO 2024 to Establish New Rare Diseases Centre of Excellence
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with...
FDA Advisers Vote In Favor Of Recommending New Covid Vaccine Target JN.1 Lineage For 2024-25 Campaign
FDA Advisers Vote In Favor Of Recommending New Covid Vaccine Target JN.1 Lineage For 2024-25 Campaign
Analysis
Price Target
No Data
